Edwards Lifesciences Corporation
EW · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $4,169,700 | $1,402,400 | $1,521,900 | $1,503,100 |
| Dep. & Amort. | $155,200 | $144,900 | $139,600 | $134,800 |
| Deferred Tax | -$323,400 | -$272,100 | -$254,500 | -$41,400 |
| Stock-Based Comp. | $162,300 | $139,400 | $126,800 | $109,300 |
| Change in WC | -$259,300 | -$526,300 | -$421,400 | $145,300 |
| Other Non-Cash | -$3,362,200 | $7,500 | $105,800 | -$119,000 |
| Operating Cash Flow | $542,300 | $895,800 | $1,218,200 | $1,732,100 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$282,400 | -$266,300 | -$264,800 | -$329,800 |
| Net Acquisitions | -$1,061,800 | -$95,200 | $0 | $329,800 |
| Inv. Purchases | -$945,800 | -$105,500 | -$778,900 | -$1,892,400 |
| Inv. Sales/Matur. | $857,600 | $715,800 | $1,359,100 | $529,200 |
| Other Inv. Act. | $3,745,300 | -$75,000 | -$63,100 | -$359,300 |
| Investing Cash Flow | $2,312,900 | $173,800 | $252,300 | -$1,722,500 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | -$300 | -$200 | -$1,800 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$1,159,400 | -$879,600 | -$1,727,100 | -$512,800 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $176,400 | $168,900 | $142,800 | $158,300 |
| Financing Cash Flow | -$983,000 | -$711,000 | -$1,584,500 | -$356,300 |
| Forex Effect | $38,600 | $16,800 | $19,200 | $13,900 |
| Net Chg. in Cash | $1,910,800 | $375,400 | -$94,800 | -$332,800 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $1,148,000 | $772,600 | $867,400 | $1,200,200 |
| End Cash | $3,058,800 | $1,148,000 | $772,600 | $867,400 |
| Free Cash Flow | $289,900 | $629,500 | $953,400 | $1,402,300 |